Alpha-Mannosidosis Clinical Trial
Official title:
A Multi-Center, Open-Label Trial of the Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis
The overall objective is to evaluate the long-term efficacy, safety and tolerability of repeated Lamazym i.v. treatment in patients 5-21 years of age with alpha-Mannosidosis
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02254863 -
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
|
Phase 1 | |
| Not yet recruiting |
NCT06184503 -
Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3
|
||
| Completed |
NCT01908725 -
Lamazym Aftercare Study
|
Phase 3 | |
| Completed |
NCT02141503 -
Clinical Biomarkers in Alpha-mannosidosis
|
||
| Recruiting |
NCT02171104 -
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
|
Phase 2 | |
| Withdrawn |
NCT04031066 -
Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis
|
Phase 3 | |
| Recruiting |
NCT03333200 -
Longitudinal Study of Neurodegenerative Disorders
|
||
| Completed |
NCT02478840 -
Evaluation of Long-term Efficacy of Treatment With Lamazym
|
Phase 3 | |
| Completed |
NCT02998879 -
Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis
|
Phase 2 | |
| Completed |
NCT01908712 -
Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients
|
Phase 3 | |
| Completed |
NCT01681953 -
A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis
|
Phase 3 | |
| Terminated |
NCT01372228 -
Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders
|
Phase 1/Phase 2 | |
| Available |
NCT04959240 -
Expanded Access to Velmanase Alfa
|